EUCTR2013-002345-11-GB进行中（未招募）1 期
A multicentre, randomised, double-blind, parallel group, placebo-controlled, Phase III efficacy and safety study of benralizumab (MEDI-563) added to high-dose inhaled corticosteroid plus long-acting beta2 agonist in patients with uncontrolled asthma (SIROCCO) - SIROCCO
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,134
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent[s]/guardian[s]) and according to international guidelines and/or applicable European Union guidelines.
- •2. Female and Male aged 12 to 75 years inclusively, at the time of visit 1. For those patients, who are 17 on the day of Visit 1 but will turn 18 after this day, will be considered an adolescent for the purposes of this trial.
- •3. History of physician diagnosed asthma requiring treatment with medium to high dose inhaled corticosteroids (greater than 250 microgrammes fluticasone dry powder formulation equivalents total daily dose) and a LABA for at least 12 months prior to visit 1
- •4. Documented treatment with ICS and LABA for at least 3 month prior to Visit 1 with or without oral corticosteroids and additional asthma controllers.
- •For subjects 18 years of age and older, the ICS dose must be greater than 500 mcg/day fluticasone propionate dry powder formulation or equivalent daily.
- •-For subjects ages 12-17, the ICS dose must be greater than or equal to 500 mcg /day fluticasone propionate dry powder formulation or equivalent daily
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 75
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1002
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 57
排除标准
- •1. Clinically important pulmonary disease other than asthma (e.g active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliarydyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome)
- •2. Any disorder including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric or major physical impairement that is not stable in the opinion of the investigator and could affect the safety of the patient throughout the study, influence the findings of the study or their interpretations, or impede the patients ability to complete the entire duration of study.
- •3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run in period.
- •4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry or urinalysis during screening/run in period, which in the opinion of the investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patients ability to complete the entire duration of the study.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthmaAsthmaMedDRA version: 18.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2013-002345-11-CZAstraZeneca AB1,134
进行中（未招募）
1 期
Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthmaAsthmaEUCTR2013-002345-11-ESAstraZeneca AB1,134
进行中（未招募）
1 期
A clinical study on the therapeutic efficacy and safety of Febuxostat and Allopurinol on serum urate concentration in subjects suffering from hyperuricemia and gouthyperuricemia and goutMedDRA version: 15.1 Level: PT Classification code 10018627 Term: Gout System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 15.1 Level: LLT Classification code 10020907 Term: Hyperuricemia System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-001858-25-ESMENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.330
进行中（未招募）
不适用
Efficacy and safety study of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus LABAMedDRA version: 17.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2013-002163-26-SEAstraZeneca AB1,296
进行中（未招募）
1 期
A clinical study on the therapeutic efficacy and safety of Febuxostat and Allopurinol on serum urate concentration in subjects suffering from hyperuricemia and gouthyperuricemia and goutMedDRA version: 17.1 Level: PT Classification code 10018627 Term: Gout System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 17.1 Level: LLT Classification code 10020907 Term: Hyperuricemia System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-001858-25-BGMENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.330